Latest News

ACCESS phase 2b data show aleniglipron 120 mg produced 11.3% placebo-adjusted weight loss at 36 weeks, with continued reductions in the OLE.

Vleugels discusses Part B findings on investigational IL-13 inhibitor zumilokibart (APG777) in adult patients with moderate-to-severe atopic dermatitis.

Teplizumab, which has recently seen a substantial label expansion into pediatric patients, is matching its safety and efficacy data in the clinic.

From a one-time CRISPR therapy cutting HAE attacks by 87% to CSU biomarkers and emerging ILIT research, here are the 5 allergy stories worth catching up on from May 2026.

This Q&A interview highlights findings on the lifelong impacts on education and career faced by some patients with childhood diagnoses of atopic dermatitis.

Hear Jim Januzzi, MD, discuss how he overcame academic shortcomings to become one of the preeminent voices in cardiology biomarkers.

Catch up on major trial results, key FDA decisions, and more.

Catch up on the key nephrology news, research findings, and expert insights featured on HCPLive throughout May 2026.

This installment of our Month in Review series highlights top news headlines and podcast updates in dermatology from May 2026.

The Genital Psoriasis Wellness Consortium reached consensus on age-specific recommendations on screening, care, and special populations.

Data suggest long-term extracorporeal photopheresis may reduce mortality risk in patients with chronic lung allograft dysfunction unresponsive to standard immunosuppression.

May 2026 saw substantial FDA decisions, major trial results, guideline updates, and more.

View the top 6 trials to watch ahead of a star-studded ADA 2026.

Phase 3 post hoc data linked lorundrostat to lower systolic blood pressure and albuminuria in patients with hypertension and CKD.

The FDA declined to approve Cingulate's once-daily ADHD therapy CTx-1301, citing CMC information requests with no clinical safety or efficacy concerns identified.

A clinician explains how sparsentan is changing treatment strategies for patients with FSGS.

Chung, MD, explains why sparsentan remains valuable in FSGS despite a negative eGFR endpoint.

A clinical forum discussed referral dynamics, access barriers, and patient health literacy challenges that shape biologic use in the real world.

FDA accepted a priority review sNDA for mavacamten in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

FDA accepts the BLA for povetacicept in IgA nephropathy, supported by positive phase 3 RAINIER trial data.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover topline data from the TRIUMPH-1 trial of retatrutide for obesity management.

Bernstein discussed the evolving role of biomarkers in chronic spontaneous urticaria at EAC 2026.